• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

MENA’s Fine Hygienic Holding Receives Promising Results for Its Livinguard Masks

Share:

June 9, 2020

Created in collaboration with the Swiss technology company, the Fine Guard face masks offer “five levels of protection against human coronavirus 229E,” and “holds promise in the fight against COVID 19.”

The Middle East & North Africa (MENA) region’s leading manufacturer of hygienic products has released promising results that its medical masks can protect against pathogens, including the coronavirus causing COVID-19. Now, its Swiss technology partner is hoping to expand on its distribution, with a focus to launch in the US.

In collaboration with the University of Arizona, Fine Hygienic Holding (FHH)’s ‘Fine Guard’ masks – which are gaining increasing popularity amongst consumers in the UAE – have undergone testing that confirms that the Livinguard textile technology incorporated into the masks “effectively neutralises pathogens of all kinds upon contact, including human coronavirus 229e [also known as HCoV-229E].”

Whilst testing wasn’t expanded to include SARS-CoV-2, it is believed that the technology would also be effective on that coronavirus, stated the company’s chief executive.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“So much research from independent third party labs in the US and Europe already showed that the textile tech applied on the masks would kill 99.9% of bacteria and viruses – they tested on many viruses from yellow fever to polio and coliphage,” said FHH CEO, James Michael Lafferty. “Because it works very well on an enveloped virus – which has a protein ring around the membrane – and because all coronaviruses are enveloped, we always believed it would work on COVID-19.

“Coronavirus 229E is the closest cousin to COVID-19 [‘s virus]. We didn’t do the test on the COVID-19 [virus] because people are still getting samples of this virus to test with. We tested with the closest cousin – both have identical surfaces and are both enveloped and one is replicable to the other.”

THE LARGER CONTEXT

Livinguard Technologies is a wholly-owned operating unit of Green Impact Holding, a Zug-based microbiology and material sciences company that equips materials with self-disinfecting technology. According to the company’s website, the Livinguard masks offer “five levels of protection against human coronavirus 229E,” and are “25x cheaper” compared to other masks.

“It has a lifetime of 6 months, replacing 210 conventional masks,” the website also states.

The scientific tests on the Fine Guard masks took place under the supervision of Dr Charles Gerba, a professor of virology at the university’s Department of Environmental Science, who confirmed: “Livinguard textile technology holds promise in the fight against COVID-19.”

Now, Livinguard is working with the US Food and Drug Administration (FDA), with the aim to introduce the masks into the US market in the coming weeks.

In the MENA region, the face masks are available in two versions: the Fine Guard N95 (which retails for $26.95), and the Fine Guard Comfort ($20.99).

ON THE RECORD

“As a leader in the wellness and hygiene industry, FHH is dedicated to providing hygienic solutions which go beyond the set market standards. Fine worked closely with Livinguard over the past couple of years to develop products that keep consumers safe and healthy,” Lafferty continued. “We are proud to be their exclusive partner in the MENA region, providing our communities and consumers with one of the most technologically advanced and effective hygienic face masks on the market today.

“We are encouraged by the confirmation of the newly-available test results from the University of Arizona and look forward to making masks treated with the Livinguard technology even more widely available.”

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • JanOne Strikes Agreement with CoreRx, a Leading cGMP Contract Manufacturer, for Phase 2B Clinical Formulation and DevelopmentJanOne Strikes Agreement with CoreRx, a Leading cGMP Contract Manufacturer, for Phase 2B Clinical Formulation and Development
  • How One Digital Healthcare Startup is Trying to Scale Across EuropeHow One Digital Healthcare Startup is Trying to Scale Across Europe
  • IGC Pharma Announces a $3 Million Private Placement of its Common StockIGC Pharma Announces a $3 Million Private Placement of its Common Stock
  • Shareholders of Abcam Approve Proposed Acquisition by DanaherShareholders of Abcam Approve Proposed Acquisition by Danaher
  • GHO Capital Acquires X-Chem, the Leading Provider of DNA-Encoded-Library-Mediated Drug Discovery ServicesGHO Capital Acquires X-Chem, the Leading Provider of DNA-Encoded-Library-Mediated Drug Discovery Services
  • Tris Pharma Expands ADHD Portfolio with Acquisition of NextWave PharmaceuticalsTris Pharma Expands ADHD Portfolio with Acquisition of NextWave Pharmaceuticals
  • 4 Ways Payers Could Improve Healthcare Price Transparency4 Ways Payers Could Improve Healthcare Price Transparency
  • The DNA Company Buys My Pain Sensei for Roughly $30M, Will Create New AppThe DNA Company Buys My Pain Sensei for Roughly $30M, Will Create New App

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications